凯赛生物2023年年报暨2024年一季报解读会_智能速览 2024年04月29日 23:39 关键词 营业收入 营业利润 净利润 研发投入 一季度业绩 毛利 生物制造 合成生物学 生物燃料 秸秆 生产资质审 批 生物基聚酯 新能源 光伏领域 双反政策 汽车轻量化 现代建筑 聚酰胺 生物机械 耐磨 全文摘要 凯塞生物展示了其在面对收入和毛利率下降的挑战时的经营策略和成果，通过加强产品研发和优化销售 策略成功实现了营业利润和净利润的增长。特别地，在2024年一季度实现了显著的增长，显示出了良好 的业务复苏迹象。凯塞生物也积极响应国家政策，聚焦生物制造领域，展现出了强劲的增长动力和广阔 市场前景。管理层对未来充满信心，并持续关注和执行政府政策，确立了生物制造作为公司的战略发展 方向。 讨论了凯瑟和招商局在生物制造领域的合作进展，包括成立联合工作小组和探索生物基尼龙材 料在太阳能、新能源等领域的应用，这表明两家公司正寻求通过政策支持共同促进产业的成长。同 时，双方都意识到了产业发展中存在的不确定性及挑战，如政策支持力度不足，强调了市场需求拓展的 重要性，并讨论了深化合作开发新应用场景的可能性。 中信证券和山西证券的代 ...

Revenue and Profit Growth - Revenue for Q1 2024 reached 684,521,536.95 RMB, a year-on-year increase of 35.43%[4] - Net profit attributable to shareholders of the listed company was 105,258,699.94 RMB, up 83.25% year-on-year[4] - Total operating revenue for Q1 2024 reached RMB 684.52 million, a 35.4% increase compared to RMB 505.45 million in Q1 2023[18] - Net profit attributable to parent company shareholders in Q1 2024 was RMB 105.26 million, up 83.3% from RMB 57.44 million in Q1 2023[19] - Basic earnings per share (EPS) for Q1 2024 were RMB 0.18, an 80% increase from RMB 0.10 in Q1 2023[20] - Basic and diluted earnings per share both increased by 80.00% to 0.18 RMB per share[8] R&D Investment - R&D investment totaled 44,784,258.67 RMB, a decrease of 9.89% year-on-year[4] - R&D investment as a percentage of revenue decreased by 3.29 percentage points to 6.54%[5] - R&D expenses in Q1 2024 decreased by 9.9% to RMB 44.78 million from RMB 49.70 million in Q1 2023[18] Cash Flow and Operating Activities - Net cash flow from operating activities surged to 215,276,527.96 RMB, a 171.65% increase compared to the same period last year[4] - Cash flow from operating activities in Q1 2024 was RMB 649.16 million, a 33.8% increase compared to RMB 485.11 million in Q1 2023[21] - Operating cash flow net amount: 215,276,527.96, an increase of 79,246,727.84 compared to the previous period[22] - Cash paid for goods and services in Q1 2024 was RMB 366.11 million, a 21.7% increase compared to RMB 300.90 million in Q1 2023[21] Assets and Liabilities - Total assets at the end of the reporting period were 18,617,743,763.23 RMB, a slight decrease of 1.14%[5] - Total assets decreased from RMB 18,833,372,759.88 to RMB 18,617,743,763.23, a decrease of approximately 1.15%[17] - Current assets decreased from RMB 7,570,668,208.85 to RMB 7,151,482,571.06, a decrease of approximately 5.53%[15] - Non-current assets increased from RMB 11,262,704,551.03 to RMB 11,466,261,192.17, an increase of approximately 1.81%[16] - Total liabilities decreased from RMB 4,060,262,557.16 to RMB 3,753,843,629.70, a decrease of approximately 7.55%[17] - Current liabilities decreased from RMB 3,409,752,675.79 to RMB 2,753,663,906.38, a decrease of approximately 19.24%[16] - Non-current liabilities increased from RMB 650,509,881.37 to RMB 1,000,179,723.32, an increase of approximately 53.76%[17] - Shareholders' equity increased from RMB 14,773,110,202.72 to RMB 14,863,900,133.53, an increase of approximately 0.61%[17] Cash and Cash Equivalents - Cash and cash equivalents decreased from RMB 5,390,218,174.98 to RMB 4,987,762,122.15, a decrease of approximately 7.47%[15] - Net increase in cash and cash equivalents: -218,561,556.52, an improvement of 156,098,219.90 compared to the previous period[22] - Ending cash and cash equivalents balance: 4,795,218,006.40, a decrease of 1,055,199,460.73 compared to the previous period[22] Accounts Receivable and Inventory - Accounts receivable increased from RMB 243,255,891.12 to RMB 291,690,168.89, an increase of approximately 19.91%[15] - Inventory decreased from RMB 1,466,355,603.97 to RMB 1,374,593,313.28, a decrease of approximately 6.26%[15] Operating Costs and Expenses - Operating costs for Q1 2024 were RMB 559.74 million, a 26.7% increase compared to RMB 441.82 million in Q1 2023[18] - Sales expenses in Q1 2024 were RMB 12.29 million, a slight 1.9% increase from RMB 12.07 million in Q1 2023[18] - Management expenses decreased by 33.6% to RMB 43.24 million in Q1 2024 from RMB 65.18 million in Q1 2023[18] Investment and Financing Activities - Cash outflow for investment activities: 463,229,410.48, a decrease of 23,865,493.07 compared to the previous period[22] - Cash inflow from financing activities: 728,258,447.26, an increase of 430,958,447.26 compared to the previous period[22] - Net cash flow from financing activities: 28,319,643.87, a decrease of 125,491,078.35 compared to the previous period[22] Government Subsidies and Non-Recurring Gains - Government subsidies contributed 3,143,696.20 RMB to non-recurring gains[6] Shareholder Information - The top shareholder, Cathay Industrial Biotech Ltd., holds 28.32% of the company's shares[9] Comprehensive Income - Total comprehensive income for Q1 2024 was RMB 104.78 million, a 49.2% increase from RMB 70.23 million in Q1 2023[19] Accounting Standards - The company did not apply new accounting standards or interpretations in 2024[23] Market Demand and Product Expansion - The company's long-chain dicarboxylic acid sales and revenue increased significantly due to market demand recovery and new product expansion[8]

Financial Performance - The net profit attributable to shareholders for 2023 was ¥366,524,351.34, with the parent company achieving a net profit of ¥3,865,342.75[5] - The company reported a revenue of RMB 1.5 billion for the fiscal year 2023, representing a year-over-year growth of 25%[12] - The company's operating revenue for 2023 was CNY 2,114,174,868.81, a decrease of 13.39% compared to CNY 2,441,103,971.54 in 2022[23] - Net profit attributable to shareholders for 2023 was CNY 366,524,351.34, down 33.75% from CNY 553,265,973.38 in 2022[25] - Basic earnings per share for 2023 was CNY 0.63, a decline of 33.68% compared to CNY 0.95 in 2022[24] - The gross margin improved to 45%, up from 40% in the previous year, due to operational efficiencies[12] - The company's total assets increased by 5.64% to CNY 18,833,372,759.88 at the end of 2023 from CNY 17,827,280,594.67 at the end of 2022[23] - The net cash flow from operating activities decreased by 29.14% to CNY 569,451,269.46 in 2023 from CNY 803,673,724.79 in 2022[25] Dividend Distribution - The company plans to distribute a cash dividend of ¥1.90 per 10 shares, resulting in a total cash dividend of ¥110,449,952.60 (including tax) based on the total share capital of 583,378,039 shares[5] - The cash dividend represents 38.73% of the net profit attributable to shareholders for the year[5] - The profit distribution policy requires approval from the board of directors and a majority vote from shareholders at the general meeting[200] - The company aims to distribute at least 10% of the annual distributable profit in cash after reserving statutory and surplus reserves[198] Business Expansion and Investments - The company announced a fundraising plan to raise no more than ¥6.6 billion to support business expansion in the field of bio-based materials[2] - Strategic investments were made in 2023, including a stake in the AI protein design platform company, Molecular Heart, and a joint venture agreement with 3P.COM focused on composite material design[2] - The company plans to raise up to 6.6 billion RMB through a private placement to support business expansion in the field of bio-based materials[35] - A strategic acquisition of a biotechnology firm was completed, enhancing the company's R&D capabilities and expected to contribute an additional RMB 100 million in revenue[12] Research and Development - Research and development expenses accounted for 8.95% of operating revenue in 2023, an increase of 1.26 percentage points from 7.69% in 2022[24] - The company emphasizes independent research and development, supported by collaborative efforts, focusing on synthetic biology and high-throughput research platforms[46] - The company is focused on enhancing its research capabilities in synthetic biology and aims to support the development of strategic emerging industries[49] - The company has invested RMB 300 million in new technology development focused on synthetic biology[12] Market Presence and User Growth - User data indicates an increase in active users by 30% compared to the previous year, reaching a total of 2 million active users[12] - The company is expanding its market presence in Southeast Asia, with plans to establish two new facilities by the end of 2024[12] - The company aims to enhance its market share by exploring industry consolidation opportunities and optimizing internal potential in response to potential market competition[65] Product Development and Innovation - The company has successfully completed pilot tests for its bio-based piperidine and is moving towards industrialization at a scale of 10,000 tons[2] - New product launches include a biomanufacturing platform expected to generate an additional RMB 200 million in revenue in 2024[12] - The company has developed a range of polyamides, including PA66 and PA6, which are widely used in various applications[15] - The company is developing bio-based polyamide thermoplastic composites reinforced with glass fiber and carbon fiber, which offer advantages such as lightweight, high strength, temperature resistance, and corrosion resistance, applicable in industries like new energy equipment and construction[42] Risk Management - The company is facing risks related to the loss of technical personnel, which could slow down R&D progress and impact competitive advantage[90] - There is a risk of core technology leakage, which could adversely affect the company's development and increase legal costs[91] - The company is exposed to raw material and energy price fluctuations, which could negatively impact operating performance if costs rise significantly[94] - The company faces risks from inventory devaluation, which could occur if market conditions lead to a significant drop in prices[99] Governance and Management - The company has a diverse board with members holding various positions, including independent directors and supervisors, ensuring governance and oversight[168] - The company has maintained a stable executive team with no significant changes in shareholding or compensation among key personnel[168] - The company emphasizes talent development by combining internal training with external recruitment to meet the demands of R&D and new projects[162] - The company has established a strong governance structure with significant shareholding by actual controllers and senior management[171] Sustainability and Environmental Commitment - The company aligns with national goals for carbon neutrality, aiming for a 13.5% reduction in energy consumption and an 18% reduction in carbon emissions per unit of GDP during the 14th Five-Year Plan period[49] - The company is committed to developing green low-carbon technologies and aims to establish a robust innovation ecosystem for bio-based materials by 2025[49] - The production of bio-based polyamide reduces carbon emissions by approximately 50% compared to traditional nylon 66 or nylon 6[86] Strategic Partnerships - The company has established long-term partnerships with major firms such as DuPont and Evonik, enhancing its market position[88] - The company has signed a business cooperation agreement with China Merchants Group to promote the use of bio-based polyamides in various sectors, including logistics and construction, enhancing sales and capacity utilization[149]

证券代码：688065 证券简称：凯赛生物 公告编号：2024-015 上海凯赛生物技术股份有限公司 关于持股 5%以上股东减持超过 1%的提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次权益变动不触及要约收购，不会导致公司控股股东及实际控制人发 生变化。 本次权益变动后，天津四通陇彤缘企业管理合伙企业（有限合伙）(以下 简称"天津四通")及其一致行动人 Seasource Holdings Limited(以下简称 "Seasource")持有上海凯赛生物技术股份有限公司（以下简称"公司"）股份 34,751,700 股，持股比例从 7.060%减少至 5.957%。 公司于 2024 年 4 月 22 日收到股东天津四通及 Seasource 出具的告知函，现 将其有关权益变动情况公告如下： | | 名称 1 | 天津四通陇彤缘企业管理合伙企业（有限合伙） | | --- | --- | --- | | 信息披 | 注册地址 | 天津自贸试验区（中心商务区）新华路 3678 号宝风大厦（新 ...

Financial Projections - The company expects Q1 2024 revenue to be between 650 million and 720 million CNY, representing a year-over-year increase of 28.60% to 42.45%[2] - The projected net profit attributable to shareholders for Q1 2024 is estimated to be between 94 million and 115 million CNY, reflecting a year-over-year growth of 63.65% to 100.20%[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 91 million and 112 million CNY, indicating a year-over-year increase of 79.04% to 120.36%[2] Previous Financial Performance - In Q1 2023, the company reported revenue of 505.45 million CNY and a net profit of 57.44 million CNY[3] Market Factors - The significant increase in sales volume and revenue is attributed to the recovery in downstream demand and the company's efforts to expand the market for new products, particularly dodecanedioic acid[5] Financial Reporting - The financial data provided is preliminary and has not been audited by an accounting firm, with final figures to be disclosed in the official Q1 2024 report[6]

证券代码：688065 证券简称：凯赛生物 公告编号：2024-013 上海凯赛生物技术股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露之日，天津四通陇彤缘资产管理合伙企业（有限合伙）（以 下简称"天津四通"）及其一致行动人 Seasource Holdings Limited（以下简称 "Seasource"）合计持有上海凯赛生物技术股份有限公司（以下简称"公司"） 36,595,000 股股份，占公司总股本的 6.273%。其中，天津四通持有公司 33,896,302 股股份，占公司总股本的 5.810%；Seasource 持有公司 2,698,698 股 股份，占公司总股本的 0.463%。 上述股份来源为公司首次公开发行股票并上市前持有的股份以及 2022 年 7 月公司实施资本公积转增股本相应增加的股份，上述股份已于 2023 年 8 月 14 日 上市流通。 减持计划的主要内容 根据自身资金需求，公司股东天津四 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2024-012 上海凯赛生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至 2024 年 3 月 31 日，上海凯赛生物技术股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易方式回购公司股份 916,964 股,占公司总股本 583,378,039 股的比例为 0.1572%。回购成交的最高价为 57.37 元/股，最低价为 45.40 元/股，支付的资金总额人民币 47,930,007.80 元（不含 印花税、交易佣金等交易费用）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司回购股份情况公告如下： 截至 2024 年 3 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式回购公司股份 916,964 股,占公司总股本 583,378,039 股的比例为 0.1572%。 回购成交 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2024-009 上海凯赛生物技术股份有限公司 关于部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2024 年 3 月 13 日分 别召开第二届董事会第十七次会议、第二届监事会第十五次会议，审议通过了《关 于部分募投项目延期的议案》，同意公司对募投项目"年产 50 万吨生物基戊二胺 及 90 万吨生物基聚酰胺项目"达到预定可使用状态的时间进行延期。上述议案无 需提交公司股东大会审议。现将相关情况公告如下： 一、募集资金基本情况 二、募集资金投资项目情况 根据公司《首次公开发行股票并在科创板上市招股说明书》披露，公司首次公 开发行股票募集资金投资项目及募集资金使用计划具体如下： 单位：人民币万元 经中国证券监督管理委员会《关于同意上海凯赛生物技术股份有限公司首次公 开发行股票注册的批复》（证监许可[2020]1439 号）同意注册，公司于 2020 年向 社会公开发行人民币普通股 41,668, ...

证券代码：688065 证券简称：凯赛生物 公告编号：2024-010 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《上海 凯赛生物技术股份有限公司关于部分募投项目延期的公告》（公告编号：2024-009）。 特此公告。 上海凯赛生物技术股份有限公司 一、监事会会议召开情况 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2024 年 3 月 5 日向全 体监事以邮件方式发出会议通知，并于 2024 年 3 月 13 日 15:00 以通讯会议的方式召 开第二届监事会第十五次会议。本次会议由监事会主席张国华主持，会议应到 3 人， 实到 3 人。本次会议的召集、召开符合《中华人民共和国公司法》等法律、法规、规 章、规范性文件和《公司章程》的有关规定，表决形成的决议合法、有效。 二、监事会会议审议情况 审议通过《关于部分募投项目延期的议案》 经审议，监事会认为：本次募投项目延期不存在变相改变募集资金投向和损害股 东特别是中小股东利益的情形，决策和审批程序符合《上市公司监管指引第 2 号— 上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板上市公司自律监 管指引第 ...

中信证券股份有限公司、招商证券股份有限公司 根据公司《首次公开发行股票并在科创板上市招股说明书》披露，公司首次 公开发行股票募集资金投资项目及募集资金使用计划具体如下： 2020年11月30日，公司第一届董事会第十五次会议和第一届监事会第十一次 会议审议通过了《关于变更部分募投项目实施主体和实施地点的议案》，同意将 公司募投项目之一"凯赛（金乡）生物材料有限公司4万吨/年生物法癸二酸项目" 变更为"40000吨/年生物法癸二酸建设项目"，由公司控股子公司凯赛（太原） 生物技术有限公司实施。具体内容详见公司于2020年12月1日在上海证券交易所 网站（www.sse.com.cn）披露的《关于变更部分募投项目实施主体和实施地点的 公告》（公告编号：2020-020）。 关于上海凯赛生物技术股份有限公司 部分募投项目延期的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）、招商证券 股份有限公司（以下简称"招商证券"、"保荐人"）作为上海凯赛生物技术股 份有限公司（以下简称"凯赛生物"、"上市公司"、"公司"）持续督导工作 的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股 票 ...